NetScientific PLC PDS expands CRADA with National Cancer Institute
30 Abril 2020 - 8:06AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
30 April 2020
NetScientific plc
("NetScientific" or the "Company")
PDS Biotechnology Expands CRADA with the National Cancer
Institute to Include Second Versamune(R)-Based Anti-Cancer
Product
London, UK - 30 April 2020 - NetScientific plc (AIM: NSCI), the
transatlantic healthcare IP commercialisation Group, today
announces that its portfolio company PDS Biotechnology Corporation
("PDS") (Nasdaq: PDSB) announced yesterday (29 April 2020) an
expansion of its previously announced Cooperative Research and
Development Agreement (CRADA) with the National Cancer Institute
(NCI) to include studies of PDS0103, a Versamune(R)-based product
incorporating novel mucin-1 (MUC1) epitopes developed by the NCI.
This expansion adds to the NCI's ongoing evaluation of PDS0101 in
combination with two separate immune-modulating agents, NHS-IL12
and M7824, which will be evaluated in a phase 2 clinical trial in
advanced HPV-associated cancers (NCT04287868).
Below is the full announcement made yesterday (29 April 2020) by
PDS Biotechnology.
# # #
PDS Biotechnology Expands CRADA with the National Cancer
Institute to Include Second Versamune(R)-Based Anti-Cancer
Product
NCI to study PDS0103, in addition to planned Phase 2 clinical
evaluation of PDS0101 in combination with other therapeutic
agents
Princeton, NJ, April 29, 2020 - PDS Biotechnology Corporation
(Nasdaq: PDSB), a clinical-stage immunotherapy company developing
novel cancer therapies and infectious disease vaccines based on the
Company's proprietary Versamune(R) T-cell activating technology,
today announced an expansion of its previously announced
Cooperative Research and Development Agreement (CRADA) with the
National Cancer Institute (NCI) to include studies of PDS0103, a
Versamune(R)-based product incorporating novel mucin-1 (MUC1)
epitopes developed by the NCI. This expansion adds to the NCI's
ongoing evaluation of PDS0101 in combination with two separate
immune-modulating agents, NHS-IL12 and M7824, which will be
evaluated in a phase 2 clinical trial in advanced HPV-associated
cancers (NCT04287868).
Under the expanded CRADA, PDS Biotech will collaborate with the
NCI Center for Cancer Research's Genitourinary Malignancies Branch
(GMB) and the Laboratory of Tumor Immunology and Biology (LTIB) to
conduct preclinical studies of PDS0103, and potentially human
clinical studies in combination with other therapeutic agents.
PDS0103 combines Versamune(R) with novel highly immunogenic agonist
epitopes of the mucin-1 (MUC1) oncogenic C-terminal region,
designed and developed by the LTIB. PDS0103 is targeting ovarian,
breast, colorectal and lung cancers where over-expression of MUC1
is associated with a high degree of unmet need.
"We are excited to further our collaboration with Dr. Schlom,
Dr. Gulley, and their teams at the NCI to progress the development
of PDS0103 and expand the CRADA beyond the previously announced
collaboration involving PDS0101. PDS0103 monotherapy has
demonstrated encouraging results in ongoing preclinical studies,"
commented Dr. Bedu-Addo, Chief Executive Officer of PDS
Biotechnology. "Based on the strong T-cell activation potential of
the Versamune(R)-based products, we believe that PDS0101 and
PDS0103 present an opportunity to improve immunotherapeutic
treatment outcomes across multiple cancer indications. We look
forward to working with the NCI as we jointly advance the
development of PDS0101 and PDS0103."
Dr. Jeffrey Schlom, Chief, LTIB, and Dr. James Gulley, Chief,
GMB, at NCI will serve as principal investigators for the NCI for
both the PDS0101 and PDS0103 programs, while Dr. Frank Bedu-Addo
and Dr. Lauren Wood, PDS Biotech's Chief Medical Officer, will
serve as the Company's investigators.
Dr. Julius Strauss, Staff Clinician, LTIB, will serve as the
principal investigator of the phase 2 clinical trial of PDS0101 in
advanced HPV-associated cancers. For patients interested in
enrolling in this clinical study, please call NCI's toll-free
number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615),
email
NCIMO_Referrals@mail.nih.gov, and/or visit the website:
https://trials.cancer.gov .
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a
growing pipeline of cancer immunotherapies and infectious disease
vaccines based on the Company's proprietary Versamune(R) T-cell
activating technology platform. Versamune(R) effectively delivers
disease-specific antigens for in vivo uptake and processing, while
also activating the critical type 1 interferon immunological
pathway, resulting in production of potent disease-specific killer
T-cells as well as neutralizing antibodies. PDS Biotech has
engineered multiple therapies, based on combinations of
Versamune(R) and disease-specific antigens, designed to train the
immune system to better recognize disease cells and effectively
attack and destroy them. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About PDS0101
PDS Biotech's lead candidate, PDS0101, combines the utility of
the Versamune(R) platform with targeted antigens in HPV-expressing
cancers. In partnership with Merck, PDS Biotech is advancing a
combination of PDS0101 and KEYTRUDA(R) to a Phase 2 study in first
line treatment of recurrent or metastatic head and neck cancer. In
partnership with the National Cancer Institute (NCI), PDS Biotech
is advancing a combination of PDS0101, M7824 and NHS-IL12 to a
Phase 2 study in advanced HPV-associated cancers. A third phase 2
study in advanced localized cervical cancer combines PDS0101 with
standard of care chemoradiotherapy.
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
Ian Postlethwaite, CEO/CFO
WHIreland (NOMAD, Financial Adviser Tel: +44 (0)20 7220 1666
and Broker)
Chris Fielding / Darshan Patel
MO PR ADVISORY (Press Contact) Tel: +44 (0)78 7644 4977
Mo Noonan
About NetScientific
NetScientific PLC is a transatlantic healthcare IP
commercialisation Group focused on technologies and companies that
have the potential to treat chronic disease and significantly
improve the health and well-being of people.
For more information, please visit the website at www.NetScientific.net
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFBLFXBZLBBBX
(END) Dow Jones Newswires
April 30, 2020 07:06 ET (11:06 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024